tnp-2092
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2016 (NCT06178718)
Timeline
Indications
Mechanism of action
rpoB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06889701 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2025 | TenNor Therapeutics Ltd, Xinjiang Medical University |
| NCT06394518 | Phase 1 | Jul 7, 2022 | TenNor Therapeutics Ltd |
| NCT05074134 | Phase 1 | Oct 11, 2021 | TenNor Therapeutics Ltd |
| NCT06135675 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2020 | TenNor Therapeutics Ltd |
| NCT04294862 | Phase 1 | Mar 31, 2020 | TenNor Therapeutics Ltd |
| NCT03964493 | Phase 2 | Apr 20, 2019 | TenNor Therapeutics Ltd |
| NCT06337604 | Phase 1 | Oct 10, 2017 | TenNor Therapeutics Ltd |
| NCT06190340 | Phase 1 | Nov 7, 2016 | TenNor Therapeutics Ltd |
| NCT06178718 | Phase 1 | Jun 6, 2016 | TenNor Therapeutics Ltd |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TenNor Therapeutics Ltd | For profit | 9 | 9 | 2 | 2016 |
| Xinjiang Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1